BMO Capital Reaffirms Their Hold Rating on Saia (SAIA)

BMO Capital analyst Fadi Chamoun maintained a Hold rating on Saia (SAIA – Research Report) today and set a price target of $280.00. The company's shares opened today at $257.50.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Chamoun covers the Industrials sector, focusing on stocks such as Saia, CAE, and Canadian National Railway. According to TipRanks, Chamoun has an average return of 13.3% and a 63.38% success rate on recommended stocks.
In addition to BMO Capital, Saia also received a Hold from Bank of America Securities's Ken Hoexter in a report issued yesterday. However, on the same day, Benchmark Co. maintained a Buy rating on Saia (NASDAQ: SAIA).
The company has a one-year high of $624.55 and a one-year low of $229.12. Currently, Saia has an average volume of 791.5K.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Insider

5 hours ago

• Business Insider

Dassault Systemes price target lowered to EUR 27 from EUR 28 at Jefferies

Jefferies lowered the firm's price target on Dassault Systemes (DASTY) to EUR 27 from EUR 28 and keeps an Underperform rating on the shares. The firm says ongoing macro uncertainty means positive surprises are unlikely in the company's Q2. It believes questions over whether Dassault will meet guidance are persist until year-end. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

6 hours ago

• Business Insider

Sarepta price target lowered to $30 from $84 at JPMorgan

JPMorgan lowered the firm's price target on Sarepta (SRPT) to $30 from $84 and keeps an Overweight rating on the shares. The firm made changes to its revenue assumptions for key Elevidys post the disclosure of second non-ambulatory patient death. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Business Insider

6 hours ago

• Business Insider

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

JPMorgan analyst Anupam Rama lowered the firm's price target on Sage Therapeutics (SAGE) to $8.50 from $11 and keeps a Neutral rating on the shares. The firm cites the acquisition deal price by Supernus Pharmaceuticals for the target cut. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>